about
Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study.Antidepressant use and cognitive decline in community-dwelling elderly people - The Three-City CohortDevelopment and validation of hospital information system-generated indicators of the appropriateness of oral anticoagulant prescriptions in hospitalised adults: the PACHA study protocol.Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in FranceAgreement between hospital discharge diagnosis codes and medical records to identify metastatic colorectal cancer and associated comorbidities in elderly patients.Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study.How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice? A study in a French teaching hospital.Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users.Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.Drug use in French children: a population-based study.Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort.Validity of chronic drug exposure presumed from repeated patient interviews varied according to drug class.Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database.Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort.National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study.Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users.Definition of indicators of the appropriateness of oral anticoagulant prescriptions in hospitalized adults: Literature review and consensus (PACHA study).Engagement in leisure activities and benzodiazepine use in a French community-dwelling elderly population.Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.NSAIDs discontinuation and myocardial infarctionEffectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohortValvular heart disease in a patient taking benfluorex[How people use the internet to find information on medicines?]
P50
Q33412222-B5D72602-561B-45F3-818A-31D9D5B2C01BQ33582388-8F17A43A-970A-4BF3-B91B-320E9F300EC8Q38599156-195C794E-AC41-444C-B12E-E20ADE60BD3DQ38606845-F66B1D14-03D3-43A6-BF2B-3C49D8F7A19DQ38650895-F8FF4C74-EC58-4E10-B250-02FFD6B2A394Q38747842-62989952-3C36-4492-8B93-62144371237BQ38749318-29F26746-5E16-42D6-ACE6-93B61ABAD4F4Q39221733-8057D118-D5DF-400B-B649-7C181CDC9067Q39418123-38B96F03-1096-4479-9976-C3C96C74293CQ39882062-B5566A56-34F5-4B15-9B1D-9551B03665ACQ40511222-7807268D-88C1-4F4C-A3ED-9F91D808F65CQ40616446-DE81E283-8552-4B64-A471-17FAB0529E53Q40936661-5DC5A982-40A9-490C-94FB-878D88ECFA10Q44390387-2859EE89-D56A-40AF-AAA2-986F3FD18EB0Q45735669-88089580-1388-49B2-993D-41D70D0A18E3Q47358924-DBF39E8D-EDE8-4978-8947-0A00D5A2B037Q47746831-D657A227-A770-46B7-ACBB-A20262A754E5Q48051950-F4B83356-FBDE-4172-8213-EEC82B36593EQ48296939-3ED5E1A5-D806-4CC3-B56B-4795259B6C30Q48299118-0A50DAA4-2FCB-4784-908E-95DA3F6BFFD0Q49885519-EA3825B7-8157-49E0-9F0A-630B56B95D25Q50788621-CEA6F865-F513-4D65-92A1-6888D572F012Q52663805-D27AE3DE-C44B-4547-92CD-5BEE6C798EEAQ57521252-47BFD6D9-C074-43E5-A88B-47F9B6525E92Q63322442-61E9686F-BF73-4769-A9F5-ED5E7BCADF8AQ79364538-953224B5-889A-4228-B90C-10819541810EQ88073919-09BDB796-1D1E-469C-9605-54568DB35865
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pernelle Noize
@ast
Pernelle Noize
@en
Pernelle Noize
@es
Pernelle Noize
@nl
type
label
Pernelle Noize
@ast
Pernelle Noize
@en
Pernelle Noize
@es
Pernelle Noize
@nl
prefLabel
Pernelle Noize
@ast
Pernelle Noize
@en
Pernelle Noize
@es
Pernelle Noize
@nl
P106
P31
P496
0000-0001-5617-7954